ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 528

Calcium-Calcineurin-NFAT Signaling Pathway Regulates AQP5 Expression in Primary Salivary Gland Acinar Cells

Shyh-Ing Jang1, Hwei Ling Ong1, Indu Ambudkar2 and Illias Alevizos3, 1Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, 2NIDCR, MPTB, NIH, Bethesda, MD, 3NIDCR, Bethesda, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Salivary gland

  • Tweet
  • Email
  • Print
Session Information

Title: Sjogren's Syndrome: Pathophysiology

Session Type: Abstract Submissions (ACR)

Background/Purpose Aquaporin (AQP) 5 belongs to a family of small integral membrane proteins which function as a water channels in cells. AQP5 plays a critical role in mediating the secretion of fluid in salivary gland. Decrease or no saliva flow is one of the key symptoms in Sjögren’s syndrome patients. Towards understanding the molecular basis of the loss of salivary secretion, here we have studied the regulation of AQP5 expression in primary human salivary gland epithelial cells (phSG). 

Methods cell culture, Western blot, qPCR, siRNAs, site-directed mutagenesis,  chromatin immunoprecipitation 

Results We observed that the phenotype of the cells depended largely on the calcium levels in the culture conditions. AQP5 transcript showed more than 3-fold increase in phSG cells grown in high calcium (0.8 mM) medium compared to that in low calcium (0.05 mM) condition. This was confirmed by both immunofluorescence staining and Western blot studies. Evaluation of expression transcripts of calcium signaling proteins in phSG cells revealed that NFAT1 expression was dependent on calcium in a dose-response manner. Furthermore, when cells were switched to a high calcium medium pGFP-NFAT1 was translocated from the cytoplasm into the nucleus. Expression of AQP5 was also reduced when phSG cells were treated with cyclosporine A confirming the involvement of calcineurin-NFAT1 signaling pathway in regulation of AQP5 expression. Since NFAT activation has been linked to calcium influx, we examined the role of the calcium entry regulatory proteins STIM1 and STIM2 as well as the channel protein Orai1. Knockdown of NFAT1 and STIM1, but not STIM2 or Orai1, resulted in 70% decrease of AQP5 expression. Further analysis revealed that several NFAT binding motifs were identified in the AQP5 promoter and these were validated using AQP5-promoter-luciferase assays. Mutagenesis of putative NFAT-binding regions as well as chromatin immunoprecipitation analyses revealed the presence of functional NFAT binding sites within the proximal AQP5 promoter region.

Conclusion These data demonstrate that AQP5 expression in phSG cells is regulated by a calcineurin-NFAT-dependent signaling pathway. Importantly, STIM1, but not Orai1 is involved in this mechanism. We propose that external Ca2+-dependent Ca2+ entry triggers activation of AQP5 expression in phSG cells. Thus alterations in calcium signaling could lead to alterations in AQP5 expression and function in pSS. Further studies are being directed towards determining the status of calcium signaling in pSS salivary glands.


Disclosure:

S. I. Jang,
None;

H. L. Ong,
None;

I. Ambudkar,
None;

I. Alevizos,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/calcium-calcineurin-nfat-signaling-pathway-regulates-aqp5-expression-in-primary-salivary-gland-acinar-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology